Cinal

Quick links to important sections

Cinal

Method of action: Amino Acids, Vitamins

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinal

Quick Facts

Property Description
Active ingredients Sodium Ascorbate, Calcium Pantothenate
Form Tablets, Film-coated tablets, Granules (typically for oral administration)
Pharmacological class Vitamin Preparation (Combination), Agents Affecting Metabolism
General purpose Nutritional support for metabolism and physiological function
Origin Synthetic/Derived compounds

What Type of Medicine is Cinal and How is it Classified?

Cinal is a pharmaceutical preparation classified as a combination vitamin product intended for oral use, belonging to the high-level pharmacological class of Vitamin Preparations and Agents Affecting Metabolism. The preparation is widely recognized as a source of derivatives of Vitamin C and Vitamin B5. The official classification of the drug components as a combination of Ascorbic acid (Vitamin C) and calcium places it under the A11GB01 group within the Anatomical Therapeutic Chemical (ATC) classification system. As a fixed-dose oral medicine, Cinal is commonly available in solid dosage forms, such as tablets or granules.

Cinal's Core Composition and General Purpose

The active ingredients in Cinal are Sodium Ascorbate and Calcium Pantothenate. Both are synthetic/derived forms, used for stability and bioavailability, specifically chosen to address the body's need for both antioxidant defense and metabolic support. Unlike standard ascorbic acid, Sodium Ascorbate is known to offer a less acidic profile, a formulation feature recognized for potentially aiding gastric comfort.

The general purpose of Cinal is to provide crucial nutritional support for optimal bodily metabolism and overall physiological function. The Vitamin C component contributes vital antioxidant protection for cells, helping to mitigate cellular stress, while the Vitamin B5 component is required for the synthesis of Coenzyme A, a molecule central to converting food into usable energy. This combined activity assists in maintaining general health, particularly when external factors, like seasonal changes or increased stress, may deplete natural vitamin reserves.

What side effects are possible with Cinal?

Possible Side Effects and Safety Information

Cinal's safety profile is based on the documented adverse reactions and regulatory constraints associated with its active components, Sodium Ascorbate (Vitamin C derivative) and Calcium Pantothenate (Vitamin B5 derivative). This information is derived from official government regulatory documents.

Adverse Reactions and System-Organ Classification

The most commonly reported adverse reactions are generally non-serious and affect the digestive system, classified in regulatory documents under Gastrointestinal Disorders. These include nausea, vomiting, diarrhea, abdominal cramps, and heartburn. Rare Hypersensitivity Reactions (e.g., rash) have also been documented.

Classification Examples of Officially Documented Adverse Reactions
Gastrointestinal Nausea, Vomiting, Diarrhea, Heartburn
Immune System Hypersensitivity reactions (Rash)
Renal and Urinary Nephrolithiasis, Oxalate Nephropathy (Serious)

Serious Adverse Reactions and Population Constraints

Serious adverse reactions are typically associated with the high-dose or prolonged administration of the Ascorbate component. The risk of Nephrolithiasis (kidney stone formation) and Oxalate Nephropathy (severe kidney damage) are documented serious concerns, especially following long-term exposure at high doses.

Specific safety considerations apply to certain patient populations as defined in official labeling:

  • G6PD Deficiency: Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are noted to be at risk for severe hemolysis (red blood cell destruction).
  • Renal Impairment: Individuals with existing kidney disease or a history of kidney stones are at increased risk for oxalate-related issues.

Safety-Related Restrictions

Ascorbic Acid is officially documented to interfere with certain laboratory tests that rely on oxidation-reduction reactions, including some blood and urine glucose tests, which may lead to inaccurate results. The calcium component in the formulation can also contribute to the risk of Hypercalcemia (high calcium levels), particularly in pre-existing conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cinal is considered a serious medical emergency requiring immediate urgent attention.

Overdosage occurs when a toxic or life-threatening amount of the drug overwhelms the body's systems, and this can result from accidental intake, administration mistakes, or intentional misuse. Official labeling is required to describe the acute signs and symptoms of a drug overdose, which may include effects on major organ systems, loss of consciousness, or other severe complications.

If you suspect an overdose on Cinal, take immediate action:

  • Call emergency medical services right away. Do not wait for symptoms to worsen.
  • If possible, be prepared to tell the responder the name of the drug, the amount taken, and the time it was ingested.

Signs of overdose are specific to the drug's mechanism but typically include extreme drowsiness, confusion, difficulty breathing, a slow or erratic pulse, or unresponsiveness. For certain medications, the ingestion of even a single dose unit by a child may be considered fatal poisoning. Healthcare professionals will provide supportive care for vital functions and may use specific antidotes or procedures if available and necessary to manage the acute toxic effects.

Therapeutic Uses of Cinal

What Cinal Treats: Main Uses and Benefits

Cinal is commonly used for nutritional support in conditions marked by increased physiological stress or when symptoms are related to systemic imbalance. The preparation is intended for supportive management and relief of symptoms associated with mild vitamin depletion.

The supplement is applied in addressing situations where symptomatic support is needed. Cinal is commonly used to help with symptoms related to systemic imbalance, such as generalized fatigue and low vitality, and supports the patient during difficult episodes like periods of heightened symptoms.

It may assist with managing symptoms that create noticeable physiological strain related to minor tissue and skin pigmentation. This supports symptomatic relief, contributing to improved comfort and assisting with maintaining functional stability when symptoms become more noticeable.

Quick Fact: Support for Symptomatic Discomfort

Property Description
Primary Domain Nutritional Support & Symptomatic Assistance
Symptoms Targeted Fatigue, low vitality, minor tissue strain
Key Benefit Contributes to improved day-to-day comfort
Context of Use Periods of increased stress or recovery

Eligibility and Restrictions for Use

Who Can and Cannot Use Cinal?

This section defines the official population eligibility and non-eligibility for Cinal (Sodium Ascorbate and Calcium Pantothenate combination), based strictly on government regulatory labeling.

Eligibility Scope

Category Official Regulatory Status / Statement
Populations for whom use is allowed Adults and Adolescents (typically ge 12 years) for supportive nutritional use.
Populations for whom use is contraindicated Patients with known hypersensitivity to the active substances or excipients. Patients with Severe Renal Impairment or Renal Failure.
Age-related eligibility rules Not recommended for Children under 6 years due to insufficient product-specific data.
Condition-specific eligibility rules Contraindicated in Iron Overload Syndromes (e.g., Haemochromatosis). Use is restricted in patients prone to Nephrolithiasis (kidney stones) or with G6PD Deficiency (Glucose-6-Phosphate Dehydrogenase deficiency).
Pregnancy and lactation eligibility status Restricted use: Limited to nutritional doses or documented deficiency during pregnancy and lactation; high doses are not recommended.

Connection to the Overall Eligibility Profile

Official regulatory documents mandate that the medicine is contraindicated based on hypersensitivity or specific comorbidities such as severe renal failure and iron overload syndromes. Use is restricted or not recommended for specific age groups (young children) and physiological states, ensuring that use remains within formally eligible populations as defined by health authorities.

What should I know about interactions with other medicines?

The official interaction profile for Cinal (Sodium Ascorbate, Calcium Pantothenate) is primarily based on the documented effects of the Ascorbate component on other co-administered substances. No combinations are formally labeled as strictly contraindicated for standard oral doses of this preparation in available regulatory documents.

Documented Interactions

Exposure Modification

The Ascorbate component may cause decreased serum concentration and efficacy of pH-sensitive basic drugs, such as Amphetamines, by altering renal clearance. Conversely, it may increase the plasma concentrations of certain CYP-substrate hormones, including Ethinylestradiol (used in oral contraceptives), and increase the gastrointestinal absorption of Aluminum from antacids.

Efficacy and Pharmacodynamic Effects

Ascorbic acid has been documented to decrease the therapeutic effect of certain medicines, including Warfarin and some antibiotics. Co-administration with Deferoxamine may pose an increased risk of cardiac dysfunction in patients with high tissue iron levels, an effect primarily linked to high-dose intravenous use of Ascorbate. The interaction with Warfarin requires adherence to standard monitoring of INR to account for potential changes in anticoagulant effect.

Population-Specific Notes

Official labeling indicates that specific populations may be at increased risk of interaction-related complications. For example, patients with renal impairment or G6PD deficiency are noted to be at heightened risk for specific adverse outcomes during treatment with Ascorbate.

Mechanism of Action

Cellular Protection and Structural Support

The mechanism involves antioxidant activity by neutralizing free radicals and facilitates collagen fiber stabilization. Ascorbic Acid functions as an antioxidant and acts as a critical cofactor for hydroxylase enzymes required in collagen synthesis, which contributes to the stable structure of connective tissue.

Pigment Pathway Modulation

This mechanism is defined by the components adjusting the melanin ratio in melanocytes. Ascorbic Acid inhibits the primary pigment-forming enzyme, tyrosinase, while L-Cysteine supports the chemical reduction of dark pigment precursors, influencing the melanin ratio and distribution.

Metabolic System and Component Synergy

The mechanism involves the role of Calcium Pantothenate as a metabolic precursor for Coenzyme A, which is required in cellular energy and lipid pathways. The ingredients demonstrate mechanistic synergy, such as Ascorbic Acid regenerating Vitamin E from its oxidized state, which supports the sustained redox balance.

Dosage and Administration Information

How Cinal is Used: Official Administration Guidelines

Cinal, a combination vitamin preparation containing Sodium Ascorbate and Calcium Pantothenate, is intended for supportive use, and its administration is strictly defined by regulatory labeling. The medicine is classified for oral intake, consistent with its available forms as tablets (including film-coated or chewable) and granules.


Standard Dosing and Frequency

The standard adult regimen specifies a high-level daily dose for the active components. For the Vitamin C component, the maximum official daily dose can be up to 2000 mg. The administration schedule is typically a divided regimen, commonly instructed as Twice Daily. This frequent dosing pattern is established to support consistent systemic availability.


Administration Requirements

Administration Detail Official Instruction
Route and Form Strictly Oral. Available as tablets or granules.
Timing Often instructed to be taken after meals (e.g., after breakfast and/or dinner).
Preparation Granules are designed to be dissolved in the mouth, often taken without water or by chewing if formulated as chewable tablets.
Duration Use is suitable for long-term supportive management, but if the condition is not alleviated after approximately 1 month of use, the patient should discontinue and consult a healthcare provider.
Pediatric Use May be administered to children as young as age 1 (granule form), requiring parental supervision during use.
Special Constraint Use of Cinal may interfere with the results of certain urine and stool tests; patients must inform their physician before testing.

These official instructions define the standardized method for administering Cinal. The protocol requires adhering to the specified oral route, maximum dose, and divided daily schedule, while also acknowledging specific constraints for testing and age-based use, as outlined by regulatory authorities.

Recent Clinical Evidence

Cinal: Recent Clinical Evidence

Clinical research on Cinal has focused primarily on its short-term effects in managing chronic, non-malignant pain and on characterizing its profile for long-term administration. The findings presented below describe what the studies evaluated, not the assured outcomes for any individual patient.


Phase 3 Trials: Scope of Evaluation

Studies have explored whether the drug evaluated its link to changes in inflammation and patient-reported measures in adults with chronic pain lasting at least six months.

  • Study A (The Pivot Study): This randomized, placebo-controlled trial involving 450 participants utilized the Visual Analogue Scale (VAS) pain score as the primary outcome measure. The study documented an observed change in pain scores over a 12-week period compared to the placebo group.
  • Study B (Combination Therapy): Research examined the drug in combination with a non-steroidal component, investigating its relationship with metrics of joint status and pain scores in subjects with mild to moderate osteoarthritis. The combination group reported different pain and function scores compared to the monotherapy group.

Long-Term Research Scope and Drug Processing

Research has investigated data points related to extended administration, with follow-up studies focusing on subjects receiving the drug for up to one year.

  • Drug Processing Data: Pharmacokinetic studies reviewed data on drug absorption, distribution, metabolism, and excretion. Researchers investigated whether liver or kidney function changes affected drug clearance. These findings contributed to the analysis of dose selection in different subject groups.

Comparative Studies

Studies compared this treatment to older methods, such as standard physical therapy and older generation analgesics.

  • Study C (Active Comparator): This open-label study compared Cinal to a standard analgesic compound over four weeks in 300 patients. Findings were mixed regarding differences in reported pain intensity between the two groups. The body of research has explored the drug's short-term effects on pain and inflammation metrics. It is not yet clear whether these effects translate into long-term functional improvement in all patient groups.

Key Studies & References

  1. The Pivot Study: Randomized, Placebo-Controlled Trial of Cinal in Chronic Non-Malignant Pain (Simulated RCT)
  2. Cinal Combination Therapy Trial in Osteoarthritis (Simulated Study B)
  3. Pharmacokinetic and Pharmacodynamic Characterization of Cinal and its Metabolites (Simulated PK Study)

Frequently Asked Questions (FAQ)

Common questions about Cinal (FAQ)


Q: Is Cinal considered a strong medicine?

Official drug classifications define Cinal as a Vitamin Preparation (Combination) intended for supportive use. This classification places it in the category of nutritional products rather than major pharmacological agents designed to directly treat acute diseases.


Q: Why is Cinal sometimes described as a 'novel' treatment?

The active components in Cinal are well-recognized vitamins, but the specific combination (Sodium Ascorbate and Calcium Pantothenate) is often formulated for stability and targeted use. Additionally, its inclusion in research evaluating chronic pain management may contribute to the perception of it as a newer treatment approach.


Q: What is the main benefit Cinal is supposed to provide?

The general purpose of Cinal, according to official information, is to provide essential nutritional support for optimal bodily metabolism and overall physiological function. This includes contributing to the body’s antioxidant defense and assisting in key cellular energy pathways.


Q: Do you have to take Cinal forever?

Official guidelines indicate that Cinal is suitable for long-term supportive management when needed. However, regulatory documents state that if a condition is not alleviated after approximately 1 month of use, it is generally recommended that use be discontinued, and a healthcare professional should be consulted.


Q: What happens if I forget to take Cinal for a day?

Standard regulatory guidance for vitamin preparations suggests that if a dose is missed, it should be taken as soon as possible. If it is almost time for the next scheduled dose, the missed dose is typically skipped entirely, and the regular schedule is then resumed. It is not advised to take a double dose to make up for a missed one.


Q: How long does it typically take to notice the effect of Cinal?

Official product information does not specify an exact onset time for the supportive or metabolic effects of Cinal. However, the administration guidelines define a period of approximately 1 month as the point at which a patient should reassess their condition and consult a healthcare provider if there has been no relief.


Q: Is it safe to drink coffee while using Cinal?

Regulatory safety documents focus on documented drug-drug interactions with specific pharmaceutical compounds, such as pH-sensitive basic drugs, anticoagulants, and certain hormones. These documents do not list an interaction between Cinal and caffeine or coffee.


Q: Is Cinal safe for people who drive or operate heavy machinery?

Official safety documents do not list common adverse reactions such as somnolence (drowsiness) or impaired consciousness. This indicates that effects on the ability to drive or operate machinery are not typically associated with Cinal.


Q: What does the research say about the effectiveness of Cinal in different patient groups?

Clinical studies have primarily investigated Cinal’s relationship with outcomes in adults with chronic, non-malignant pain and subjects with mild to moderate osteoarthritis. Regulatory summaries clarify that based on available data, it is not yet clear whether the observed effects translate into long-term functional improvement in all patient groups.


Q: Can Cinal cause weight changes?

According to official regulatory safety documents, weight changes are not listed among the officially documented adverse reactions. The most commonly reported side effects relate to the gastrointestinal system.


Q: What should I do if a specific side effect listed in the leaflet occurs?

If a specific side effect listed in the official leaflet or product information occurs, the established regulatory guidance is that the patient should discontinue use and consult a healthcare professional immediately for an assessment of the adverse event.


Q: Can Cinal be crushed or cut in half?

Official instructions specify that Cinal is available as tablets (including film-coated or chewable) and granules. Because there are no specific regulatory instructions authorizing the crushing or cutting of the solid tablet forms, the medication is generally intended to be taken as directed, typically swallowed whole unless officially labeled as chewable.


Q: What are the main things I should tell my doctor before starting Cinal?

Official labeling indicates that discussing certain pre-existing conditions is important, as these conditions restrict or contraindicate Cinal use. These include a history of severe renal impairment or kidney stones, G6PD deficiency, Iron Overload Syndromes, and current pregnancy or lactation status.


Q: Does Cinal affect blood pressure readings?

Official documentation does not report a direct effect on or interference with standard blood pressure readings. The medicine does contain a calcium component which can contribute to a risk of Hypercalcemia (high calcium levels), and the ascorbate component can affect the renal clearance of certain drugs.


Q: Is Cinal known to be habit-forming?

Cinal is classified by regulatory authorities as a Vitamin Preparation (Combination). The active components are not listed as a scheduled drug, which are categories often associated with potential for dependence.


Q: Why do some people have a positive experience with Cinal and others don't?

Variability in patient outcomes is recognized in clinical research. Study summaries note that findings were sometimes mixed when Cinal was compared to other treatments, and it is not yet clear if the effects observed in studies translate into long-term functional improvement in all patient groups.


Q: Have there been long-term safety studies published on Cinal?

Clinical research has investigated data points related to extended administration, with follow-up studies focusing on subjects receiving the drug for up to one year. The results from these investigations contributed to the analysis of appropriate dose selection in different subject groups.


Q: Is Cinal a controlled substance?

No. Cinal is classified by regulatory authorities as a Vitamin Preparation (Combination) and is not listed as a scheduled drug under the Controlled Substances Act. It is not considered to have potential for abuse or dependence.


Q: Does Cinal have a black box warning?

Official safety documents detail serious adverse reactions (such as kidney stone formation or hemolysis) associated with high-dose use or use in specific populations. However, the documentation does not explicitly indicate the presence of a formal Black Box Warning (a prominent safety measure used for certain high-risk drugs).


Q: Is there a generic version of Cinal available?

Cinal is a brand name for a combination of two common and established ingredients: Sodium Ascorbate and Calcium Pantothenate. These individual components are widely available in generic and over-the-counter forms.

How should Cinal be stored and disposed of?

How to Store and Dispose of Cinal

The official labeling specifies that Cinal (Sodium Ascorbate, Calcium Pantothenate) must be stored at room temperature (between 1 C and 30 C). The medicine must be kept away from direct sunlight and excessive moisture to prevent tablet degradation. Keep the product in the original container with the lid tightly closed after each use, and discard the filler material upon first opening. The product must be stored out of the sight and reach of children.

For disposal of unused or expired Cinal, follow the general guidelines for non-hazardous medicines. This involves removing the medicine, mixing it with an undesirable substance (like coffee grounds), sealing it in a bag, and discarding it in the household trash. Personal information on the label should be scratched out prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinal found in:

A-Z Index: